JP2015517482A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517482A5
JP2015517482A5 JP2015510838A JP2015510838A JP2015517482A5 JP 2015517482 A5 JP2015517482 A5 JP 2015517482A5 JP 2015510838 A JP2015510838 A JP 2015510838A JP 2015510838 A JP2015510838 A JP 2015510838A JP 2015517482 A5 JP2015517482 A5 JP 2015517482A5
Authority
JP
Japan
Prior art keywords
tissue targeting
complex
targeting moiety
moiety
hopo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015510838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517482A (ja
JP6211066B2 (ja
Filing date
Publication date
Priority claimed from GB201208309A external-priority patent/GB201208309D0/en
Application filed filed Critical
Publication of JP2015517482A publication Critical patent/JP2015517482A/ja
Publication of JP2015517482A5 publication Critical patent/JP2015517482A5/ja
Application granted granted Critical
Publication of JP6211066B2 publication Critical patent/JP6211066B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015510838A 2012-05-11 2013-05-13 放射性医薬錯体 Expired - Fee Related JP6211066B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201208309A GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes
GB1208309.3 2012-05-11
PCT/EP2013/059839 WO2013167754A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Publications (3)

Publication Number Publication Date
JP2015517482A JP2015517482A (ja) 2015-06-22
JP2015517482A5 true JP2015517482A5 (https=) 2017-08-17
JP6211066B2 JP6211066B2 (ja) 2017-10-11

Family

ID=46458687

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015510838A Expired - Fee Related JP6211066B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体
JP2015510839A Pending JP2015523326A (ja) 2012-05-11 2013-05-13 放射性医薬錯体
JP2015510840A Expired - Fee Related JP6219372B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015510839A Pending JP2015523326A (ja) 2012-05-11 2013-05-13 放射性医薬錯体
JP2015510840A Expired - Fee Related JP6219372B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体

Country Status (9)

Country Link
US (3) US9827336B2 (https=)
EP (3) EP2846842A1 (https=)
JP (3) JP6211066B2 (https=)
KR (3) KR20150092702A (https=)
CN (3) CN104619355A (https=)
CA (3) CA2873144C (https=)
GB (1) GB201208309D0 (https=)
HK (3) HK1206982A1 (https=)
WO (3) WO2013167754A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511266B1 (en) 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2816038B8 (en) 2009-08-24 2019-12-25 Lumiphore, Inc. Hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
US10821195B2 (en) * 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
PE20190168A1 (es) * 2016-03-24 2019-02-01 Bayer Pharma AG Complejos radiofarmaceuticos
WO2017211809A1 (en) 2016-06-10 2017-12-14 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
EP3585436A1 (en) 2017-02-24 2020-01-01 Bayer AS Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
CN111918877A (zh) * 2018-03-14 2020-11-10 美国卫生和人力服务部 抗cd33嵌合抗原受体及其用途
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
US11279698B2 (en) * 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
USD885822S1 (en) 2018-12-14 2020-06-02 Whirlpool Corporation Food grinder
CA3130747A1 (en) 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
CA3130809A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
EP4003959A1 (en) 2019-07-25 2022-06-01 Bayer AS Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
BR112022013678A2 (pt) * 2020-01-10 2022-11-16 Fusion Pharmaceuticals Inc Quelatos macrocíclicos e seus usos
AU2020424030B2 (en) * 2020-01-23 2025-05-29 Radtran Llc Systems and methods for preparing tailored radioactive isotope solutions
US20240000838A1 (en) * 2020-11-30 2024-01-04 Simcere Innovation, Inc. Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy
AU2022210371A1 (en) 2021-01-22 2023-07-20 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
AU2024339683A1 (en) 2023-09-13 2026-03-26 Toray Industries, Inc. Pharmaceutical composition for treating, preventing and/or diagnosing cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
EP2497501B1 (en) * 2004-06-25 2019-05-01 The European Union, represented by the European Commission Radionuclides for medical use
US7794691B2 (en) * 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008063721A2 (en) 2006-08-15 2008-05-29 The Regents Of The University Of California Luminescent macrocyclic lanthanide complexes
US8158804B2 (en) 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
CA2768658C (en) * 2009-07-22 2018-04-03 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
WO2011079291A1 (en) * 2009-12-24 2011-06-30 Lumiphore, Inc. Radiopharmaceutical complexes
EP2359802B1 (en) * 2010-02-12 2014-06-18 Evonik Degussa GmbH Cosmetic composition containing polyglycerol partial ester
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Similar Documents

Publication Publication Date Title
JP2015517482A5 (https=)
JP2015523326A5 (https=)
SI2533817T1 (en) Target complexes that emit alpha particles containing thorium radionuclide and a ligand containing hydroxypyridinone
JP6211066B2 (ja) 放射性医薬錯体
RU2503687C2 (ru) Сшивающие реагенты и их применение
CN110357967B (zh) 新型成像组合物及其用途
JP2010535713A5 (https=)
TWI654179B (zh) 放射性醫藥複合物
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
SI2894162T1 (en) Identification of tumor-associated antigens for diagnosis and therapy
MX2024005950A (es) Radioligandos escindibles para dirigirse a receptores de la superficie celular y sus usos.
RU2019111303A (ru) Антитела против edb и конъюгаты антитело-лекарственное средство
JP2021503915A5 (https=)
MX2024014265A (es) Complejos radiofarmaceuticos dirigidos al antigeno prostatico especifico de membrana y sus combinaciones
JP2016540826A5 (https=)
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
Nie et al. Small-Cell Lung Cancer Updates
Lewis et al. Models for B12-conjugated radiopharmaceuticals. Cobaloxime binding to new fac-[Re (CO) 3 (Me2bipyridine)(amidine)] BF4 complexes having an exposed pyridyl nitrogen
Byun et al. Preclinical Proof of Concept for the Single‐Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein
NZ766904A (en) Amanitin antibody conjugate
NZ766904B2 (en) Amanitin antibody conjugate
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
TH1801005806A (th) สารเชิงซ้อนทางเภสัชกรรมกัมมันตรังสี
NZ777968A (en) Multispecific antigen-binding molecules and uses thereof
NZ777968B2 (en) Multispecific antigen-binding molecules and uses thereof